Dr. Sharad P. Adekar M.D.
Wallingford, PA 19086
**************@*****.***
Work Authorization Status: Permanent Resident of USA
Work Address: Immunome, Inc
Lankenau Institute for Medical Research
Room No 227
100 E Lancaster Ave,
Wynnewood, PA-19096
Ph no. 484-***-****
Email: ********@***********.***
Summary
I have over 7 yrs of experience in human hetero-hybriodom development where
I have created most efficient method to generate human monoclonal
antibodies. I have used this method for generation of human monoclonal
antibodies against vaccinia virus, rabies virus, influenza virus, botulinum
neuro-toxin, clostridium difficile toxin and amyloid peptides.
Professional experience
Immunome Inc September 2008- Present
Wynnewood, PA
Director of Antibody Research
Responsible for efficient management of R&D projects via interaction with
team members.
Essential Duties and Responsibilities
. Manage the R&D group by monitoring the progress of the projects closely
on a day-today basis
. Provide scientific oversight for the activities of the R&D group; assist
the team leaders in developing R&D plans and experimental designs for all
projects
. Work on independent R&D projects to develop new antibodies
. Ensure that accurate and technically rich data sheets/protocols for all
new antibodies are written in a timely manner
. Keep in touch with the latest, cutting edge scientific research through
reading the literature and/or attending scientific meetings, seminars, etc.
. Coordinate regular R&D meetings to discuss the progress of all current
R&D projects and get feedback from other members
Key achievements in one year
Human monoclonal antibodies against clostridium difficile toxin
Designed, developed and running project on cloning of human monoclonal
antibodies against clostridium difficile toxin.
Developed cell-based assays for testing biological activity of these
antibodies.
Completed testing of neutralization activity of antibodies in mice.
Made large scale production of antibodies for Hamster studies.
Lankenau Institute for Medical Research November 2007-
Present
Wynnewood, PA
Scientist
Key achievements
Human monoclonal antibodies against Botulinum toxin
. Designed, Developed and characterized more than 20 human
monoclonal antibodies neutralizing bioterror agent
botulinum neuro-toxin.
. Antibodies have pico-molar affinity tested by kinetic
exclusion assay (KinExa).
. With these antibodies, developed ultra-sensitive assay for
detection of botulinum toxin in blood and milk samples.
Human monoclonal antibodies against abeta-peptide (Alzheimer's
disease)
. Designed, Developed and characterized around 10 human
monoclonal antibodies that bind to abeta-peptide and JTO-
light chain in Alzheimer's disease.
. Developed heavy chain only human monoclonal antibodies that
inhibit abeta-fibrils initiation and elongation.
. These antibodies bind to abeta-peptide plaques in
Alzheimer's disease brains.
Human monoclonal antibodies against Rabies virus
. Designed and developed 6 human monoclonal antibodies
against rabies virus.
Human monoclonal antibodies against Influenza virus
. Designed, Developed and characterized 4 human monoclonal
antibodies against influenza virus.
Cardeza Foundation For Hematologic Research March 2003- November 2007
Thomas Jefferson University, Philadelphia, PA
Post-doctoral Fellow
Human hybridoma technology development
. Developed a novel three step-hybridoma method that
efficiently overcomes limitations of old traditional
hybridoma method. Peripheral blood mononuclear cells
(PBMCs) are (1) selected for expression of CD27, a marker
of B-cells that express affinity-matured antibodies, (2)
cultured in vitro to promote B-cell proliferation and class-
switching, and (3) fused to a genetically modified myeloma
cell line that efficiently produces stable hybridoma cells
secreting human monoclonal antibodies.
. Created a novel fusion partner cell line that express human
telomerase (hTERT) and mouse interleukin-6 (mIL-6).
Human monoclonal antibodies against botulinum toxin
. Designed and developed project to generate human monoclonal
antibodies against botulinum toxin.
Interactive Research School For Health Affairs August 2001- March 2003
Bharti Vidyapeeth Medical College, Pune, India
Scientist and Attending Physician
. Developed a project to see role of omega-3 fatty acids in
pregnancy-induced hypertension
Education
1991-1996 M.B.B.S. B.J. Medical College, Pune, India.
1996-1997 Medical Internship. Cantonment Hospital, Pune & Primary Health
Centre, Nasarapur, India.
1997-1998 Medical Officer. Primary Health Centre, Palasdev, Indapur,
India.
1998-2001 M.D. B.J. Medical College, Pune, India.
Academic Honors
1989 S.S.C.- 17th in the merit list of Pune Board.
1991 H.S.C.- 20th in the merit list of Pune Board.
1991 National Merit Scholarship holder in Medical College.
2001 First in Pune University between M.D. and M.S.
Candidates of all different branches.
Current grant support
1R43AI079999-01 (Adekar Sharad, PI) Jan 2009-2010
A heteropolymer antibody for treatment of serotype B BoNT
NIH study section
2008 october Temporary member, study section: ZAI1 AR-M (C2)
Application of Platform Technologies for the Development of
Therapeutics for Biodefense.
Guest Lectures
Feb 2001 Poona chapter of Obstetrics & Gynecology Association
Topic: Role of Omega-3 fatty acids in Pregnancy-induced
Hypertension
Board Certification
Medical Council of India, Medicine, 1997
Medical Biochemistry, 2001
Membership
American society of microbiology
Publication
Adekar SP, Klyubin I, Macy S, Rowan MJ, Solomon A, Dessain SK, O'Nuallain
B. Inherent anti-amyloidogenic activity of human Ig {gamma} heavy chains. J
Biol Chem. 2009 Nov 4. [Epub ahead of print]
Adekar, SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ,
Kapadnis BP, Simpson LL, Dessain SK. Neutralization of botulinum neurotoxin
by a human monoclonal antibody specific for the catalytic light chain. PLoS
ONE. 2008 Aug 20;3(8):e3023.
Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL, and
Dessain, SD. Hybridoma populations enriched for affinity-matured human IgGs
yield high-affinity antibodies specific for botulinum neurotoxins. J
Immunol Methods. 2008 Apr 20;333(1-2):156-166. Epub 2008 Feb 20.
Adekar, SP, Al-Saleem, FH, Elias, MD, Simpson, LL, and Dessain, SD. A
natural human IgM antibody that neutralizes botulinum neurotoxin in vivo.
Hybridoma (Larchmt). Hybridoma (Larchmt). 2008 Apr;27(2):65-9.
Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL, and
Dessain, SD. A human monoclonal antibody that binds serotype A botulinum
neurotoxin. Hybridoma (Larchmt). Hybridoma (Larchmt). 2008 Feb;27(1):11-7.
Dessain SK, Adekar SP, Stevens JB, Carpenter KA, Skorski ML, Barnoski BL,
Goldsby RA, Weinberg RA. High efficiency creation of human monoclonal
antibody-producing hybridomas. (2004) J Immunol Methods 291(1-2):109-22.
Nonexperimental articles. (Articles in Books)
Dessain, SK, Adekar, SP, and Berry, JD. Exploring the native human
antibody repertoire to create anti-viral therapeutics. Curr Top Microbiol
Immunol. 2008;317:155-83. Review.
Oral Presentation
Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL and
Dessain, SK. Human monoclonal antibodies neutralizing botulinum neurotoxin
in vivo. 46th ICAAC, San Francisco, CA, 2006.
Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ, Simpson, LL and
Dessain, SK. Use of a novel hetero-hybridoma method to clone potent, high
affinity human antibodies specific for botulinum neurotoxins. Second Annual
Jefferson Postdoctoral Research Symposium, Thomas Jefferson University,
Philadelphia, PA, June, 2007.
Adekar, SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DM, Root MJ,
Kapadnis BP, Simpson LL, Dessain SK. Neutralization of botulinum neurotoxin
by a human monoclonal antibody specific for the catalytic light chain.
Second Annual Botulinum Research Symposium, University of Massachusetts
Dartmouth, Aug 21-22, 2008.
Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Shupp H, Root, MJ,
Kapadnis BP, Simpson, LL and Dessain, SK. Human Monoclonal Antibodies
Cloned By A Novel Hybridoma Method Neutralize Botulinum Neurotoxin in vivo.
Interagency Botulism Research Coordinating Committee Meeting,
Philadelphia, Sep 14-18,2008.
Adekar, SP, Jones, RM, Elias, MD, Tsuyoshi T, Al-Saleem, FH, Root, MJ,
Kapadnis BP, Simpson, LL and Dessain, SK. Creation of hybridoma populations
from post-germinal center B-cells and their use to clone human antibodies
specific for botulinum neurotoxins. The14th International Conference on
Human Antibodies and Hybridomas, New York, 12-14 November 2008.
Poster Presentations
Adekar, SP, Bulakh, PM, Melinkeri, RR. Role of Nitric Oxide in Renal
Diseases. Association of Clinical Biochemistry of India Annual Meeting,
Nagpur, India, 2001.
Dessain, SK, Adekar, SP, Rybinski, KA, Barnoski, B, Goldsby, RA, Weinberg,
RA. Neutralization of botulinum neurotoxin with a single human antibody
cloned using a new human antibody cloning method. Bio2005, Philadelphia,
PA, June 19-22, 2005.
Adekar, SP, Elias, MD, Rybinski, KA, Al-Saleem, FH, Maksymowych, AB,
Simpson,LL and Dessain, SK. Human Antibodies that Bind Botulinum
Neurotoxin A. International Conference on Basic and Therapeutic Aspects of
Botulinum and Tetanus Toxins, Denver, CO, June 23-25, 2005.
Dessain, SK, Rybinski, KE, Adekar, SP, Rauova, L, Sachias, BS, McKenzie,
SE, Reilly, MP. A Human Antibody, Cloned from a Patient with Heparin-
Induced Thrombocytopenia, that Binds Heparin/Platelet Factor 4 Complexes.
33rd Annual Philadelphia Workshop on Hemostasis, Thrombosis and
Atherosclerosis. Thomas Jefferson University, Philadelphia, PA, November
18, 2005.
Dessain, SK, Rybinski, KA, Adekar, SP, Raouva, L, Sachias, B, McKenzie, SE,
Reilly, MP. A human antibody, cloned from a patient with heparin-induced
thrombocytopenia, that binds heparin/platelet factor 4 complexes. American
Society of Hematology 47th Annual Meeting, Atlanta, GA, December 10-13,
2005.
Dessain, SK, Adekar, SP, Jones, RM, Elias, MD, Al-Saleem, FH, Root, MJ,
Simpson, LL. Use of a novel hetero-hybridoma method to clone potent, high
affinity human antibodies specific for botulinum neurotoxins. The13th
International Conference on Human Antibodies & Hybridomas, Milan, Italy, 29-
31 October 2007.
Dessain, SK, Adekar, SP, Klyubin, I, Macy, SD, Rowan, MJ, Solomon, A,
O'Nuallain, B. Human Immunoglobulin Heavy Chains Have Novel Fibril-binding
And Anti-amyloidogenic Activity. International Conference on Alzheimer's
Disease, Vienna, Austria, July 11-16, 2009.
US Patent Applications
Adekar, SP, Simpson LL and Dessain, SK. Monoclonal antibodies that
neutralize botulinum neurotoxin.
Patent serial no: 11/455,507
Adekar, SP, Dessain SK. A method of creating libraries of hybrid cells that
express useful antibodies.
Docket no: 37075-0225-P1-US (223452)
Adekar, SP, Dessain SK. Fusion partner cell line for preparation of hybrid
cells expressing human antibodies.
Docket no: 37075-0226-P1-US (225641)
O'Nuallain, B, Dessain SK, Adekar, SP. Use of Immunoglobulin heavy and
light chains
or fragments thereof to bind to aggregated amyloidogenic proteins.
Docket no: 747-0117